Platelets do not rise after taking Avatrombopag (Avatrombopag, Su Kexin) for 5 days

Avatrombopag/Avatrombopag is a drug used to treat certain types of thrombocytopenia, usually when surgery or other medical intervention is expected. Although the drug can effectively increase platelet count in most patients, some patients may not see a significant increase after taking it for 5 days. This situation can be caused by a variety of factors.

Each patient's physiological state, genetic profile, and response to medications are different. In some patients, the efficacy of avatrombopag may be affected due to underlying diseases, comorbidities, or other physiological factors. For example, hepatic insufficiency or renal impairment may affect drug metabolism and clearance, thereby affecting platelet production.

If a patient's thrombocytopenia is due to bone marrow dysfunction, immune disease, or other causes, treatment with avatrombopag alone may not achieve the desired effect. In this case, the doctor may need to re-evaluate the patient's condition and consider alternative treatments.

In addition, patients may experience reduced efficacy due to reasons such as forgetting to take the medication, taking the wrong dose, or failing to follow the doctor's instructions during the medication period. Therefore, it is emphasized that the importance of patients taking drugs on time and in the correct amount is emphasized to ensure that the treatment course is complete and the drug concentration is maintained within the effective range.

If the platelet level does not increase significantly during the 5-day treatment, the patient is advised to communicate with the doctor in time. The doctor may adjust the treatment plan based on the patient's specific situation, such as extending the treatment time, changing the dosage of the medication, or choosing another type of treatment. Your doctor may also perform further tests to determine if there are other potential problems affecting platelet production.

Reference materials:https://www.mayoclinic.org/drugs-supplements/avatrombopag-oral-route/description/drg-20443767